These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 17449422

  • 1. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review.
    Kaczmarek I, Deutsch MA, Sadoni S, Brenner P, Schmauss D, Daebritz SH, Weiss M, Meiser BM, Reichart B.
    J Heart Lung Transplant; 2007 May; 26(5):511-5. PubMed ID: 17449422
    [Abstract] [Full Text] [Related]

  • 2. Late humoral rejection in a cardiac transplant recipient treated with the anti-CD20 monoclonal antibody rituximab.
    Keren A, Hayes HM, O'Driscoll G.
    Transplant Proc; 2006 Jun; 38(5):1520-2. PubMed ID: 16797348
    [Abstract] [Full Text] [Related]

  • 3. ABO-incompatible deceased donor liver transplantation with the use of antigen-specific immunoadsorption and anti-CD20 monoclonal antibody.
    Boberg KM, Foss A, Midtvedt K, Schrumpf E.
    Clin Transplant; 2006 Jun; 20(2):265-8. PubMed ID: 16640538
    [Abstract] [Full Text] [Related]

  • 4. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
    Matignon M, Tagnaouti M, Audard V, Dahan K, Lang P, Grimbert P.
    Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
    [Abstract] [Full Text] [Related]

  • 5. De novo production of donor-specific anti-HLA alloantibodies in early acute humoral renal allograft rejection.
    Spriewald BM, Hugo C.
    Clin Transpl; 2006 Oct; ():469-72. PubMed ID: 18365405
    [Abstract] [Full Text] [Related]

  • 6. Antibody-mediated rejection: treatment alternatives and outcomes.
    Singh N, Pirsch J, Samaniego M.
    Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
    [Abstract] [Full Text] [Related]

  • 7. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
    Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S.
    Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
    [Abstract] [Full Text] [Related]

  • 8. The emerging role of rituximab in organ transplantation.
    Becker YT, Samaniego-Picota M, Sollinger HW.
    Transpl Int; 2006 Aug; 19(8):621-8. PubMed ID: 16827678
    [Abstract] [Full Text] [Related]

  • 9. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab.
    Baran DA, Lubitz S, Alvi S, Fallon JT, Kaplan S, Galin I, Correa R, Courtney MC, Chan M, Spielvogel D, Lansman SL, Gass AL.
    Transplant Proc; 2004 Dec; 36(10):3164-6. PubMed ID: 15686719
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
    Guillonneau C, Aubry V, Renaudin K, Séveno C, Usal C, Tezuka K, Anegon I.
    Transplantation; 2005 Aug 27; 80(4):546-54. PubMed ID: 16220623
    [Abstract] [Full Text] [Related]

  • 11. B cell monitoring of transplant patients treated with anti-CD20.
    Abdallah KO, Prak ET.
    Clin Transpl; 2006 Aug 27; ():427-37. PubMed ID: 18365400
    [Abstract] [Full Text] [Related]

  • 12. B cells: a rational target in alloantibody-mediated solid organ transplantation rejection.
    Pescovitz MD.
    Clin Transplant; 2006 Aug 27; 20(1):48-54. PubMed ID: 16556153
    [Abstract] [Full Text] [Related]

  • 13. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM, Ozawa M, Verbanac KM, Catrou P, Haisch CE, Terasaki PI.
    Clin Transpl; 2006 Aug 27; ():241-53. PubMed ID: 18365382
    [Abstract] [Full Text] [Related]

  • 14. Novelties in diagnostics and therapy of antibody mediated rejection.
    Dragun D, Rudolph B.
    Nephrol Dial Transplant; 2007 Sep 27; 22 Suppl 8():viii50-viii53. PubMed ID: 17890264
    [Abstract] [Full Text] [Related]

  • 15. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant.
    Kaczmarek I, Deutsch MA, Kauke T, Beiras-Fernandez A, Schmoeckel M, Vicol C, Sodian R, Reichart B, Spannagl M, Ueberfuhr P.
    Exp Clin Transplant; 2008 Sep 27; 6(3):229-35. PubMed ID: 18954302
    [Abstract] [Full Text] [Related]

  • 16. [Antibody-mediated acute rejection].
    Lefaucheur C, Nochy D, Glotz D.
    Nephrol Ther; 2008 Oct 27; 4 Suppl 3():S188-91. PubMed ID: 19000885
    [Abstract] [Full Text] [Related]

  • 17. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T, Rüsi B, Fischer A, Hopfer H, Wüthrich RP, Gaspert A.
    Transplantation; 2009 Jun 27; 87(12):1837-41. PubMed ID: 19543061
    [Abstract] [Full Text] [Related]

  • 18. Treatment of vascular rejection with rituximab in cardiac transplantation.
    Garrett HE, Duvall-Seaman D, Helsley B, Groshart K.
    J Heart Lung Transplant; 2005 Sep 27; 24(9):1337-42. PubMed ID: 16143254
    [Abstract] [Full Text] [Related]

  • 19. Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients.
    Aguilera I, Alvarez-Marquez A, Gentil MA, Fernandez-Alonso J, Fijo J, Saez C, Wichmann I, Nuñez-Roldan A.
    Nephrol Dial Transplant; 2008 Jul 27; 23(7):2393-8. PubMed ID: 18308775
    [Abstract] [Full Text] [Related]

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 27; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.